Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Business Archived • July 23, 2026 • 3 views

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.

Source: https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original